Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices, in the largest acquisition by the ...
Penumbra expected to generate $1.4 bln in 2025 sales; shares surge 12% Transaction values Penumbra at $374 per share, 19.3% premium to last close Penumbra CEO Adam Elsesser to join Boston Scientific's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results